Tauriga Sciences, Inc. Preparing for Multiple Major Upcoming Product Launches During This Current Operating Quarter
July 22 2020 - 11:43AM
InvestorsHub NewsWire
Additionally, the
Company Continues to Realize Material Progress with Respect to its
Two Ongoing Biotechnology
Initiatives
Retail One Pager – Pear Bellini (Immune Booster)
Tauri-Gum™
NEW YORK, NY -- July
22, 2020 -- InvestorsHub NewsWire -- Tauriga Sciences, Inc.
(OTCQB: TAUG)
(“Tauriga” or the “Company”), a revenue generating, diversified
life sciences company, with a proprietary line of functional
“supplement” chewing gums (Flavors: Pomegranate, Blood Orange,
Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two
ongoing Biotechnology initiatives, today confirmed that it is
preparing for multiple major product launches during this current
operating Quarter (July 1, 2020 – September 30, 2020) –
2ndFiscal Quarter of 2021. Over the course of
the upcoming days and weeks, the Company will be both: launching
its Rainbow Deluxe Sampler Pack (via its E-Commerce
website: www.taurigum.com) and executing the national roll-out of its
Tauri-Gum™ brand (in partnership with Mr. Checkout
Distributors).
The Company has
assembled a multi-faceted (influencer based) marketing program, to
support the upcoming launch of its Rainbow Deluxe Sampler Pack
(“Rainbow Pack”). The Rainbow Pack consists of One
Blister Pack of each Tauri-Gum™ flavor (Pomegranate, Blood Orange,
Peach-Lemon, Pear Bellini, Mint, Black Currant) and will be offered
– exclusively on the Company’s E-Commerce website – at a price of
$99.99
The Company is also
working with great diligence, in preparation for the national roll
out of its Tauri-Gum™ brand – in partnership with Mr. Checkout
Distributors (“Mr. Checkout”). This national roll-out of
Tauri-Gum™ will be supported by a national network of more than
1,100 independent Direct Store Delivery (“DSD”)
Distributors that service approximately
200,000 stores and retail locations (“locations”) across the United
States. These locations include major retail and
convenience store chains with an emphasis on gas station
convenience marts.
Link (Mr.
Checkout/Tauri-Gum™): https://mrcheckout.net/tauri-gum/ ;
Additionally, the
Company continues to realize important and material progress with
respect to its two ongoing Biotechnology
Initiatives:
- The Development
of a Pharmaceutical Grade version of Tauri-Gum™(specifically
designed for patients undergoing chemotherapy
treatment)
- The
Collaboration Agreement with Aegea Biotechnologies Inc. to develop
a rapid (nucleic acid based), multiplexed Novel Coronavirus
(COVID-19) Test designed to exhibit superior
performance
The Company expects to
provide its shareholders with material updates (via press
releases), over the course of both the short and intermediate
terms.
Tauriga’s CEO Seth M.
Shaw expressed, “The Company believes that these major upcoming
product launches have the potential to be transformative – with
respect to both revenue growth as well as the national prominence
of its flagship Tauri-Gum™ brand. The Company continues
to experience overall strength in its highest margin E-Commerce
business segment, and in addition to that, is experiencing organic
growth in its social media presence (i.e. Instagram Followers) and
daily web traffic on its E-Commerce website. Equally
exciting is the important progress that the Company has realized
with respect to its two ongoing biotechnology
initiatives. The Company is making important progress
across the board and is looking forward to sharing this progress
with both its shareholders and
stakeholders.”
ABOUT TAURIGA SCIENCES
INC.
Tauriga Sciences, Inc.
(TAUG)
is a revenue generating, diversified life sciences company, engaged
in several major business activities and initiatives. The
company manufactures and distributes several proprietary retail
products and product lines, mainly focused on the Cannabidiol
(“CBD”) and Cannabigerol (“CBG”) Edibles market
segment. The main product line, branded as Tauri-Gum™,
consists of a proprietary supplement chewing gum that is both
Kosher certified and Vegan formulated (CBD Infused Tauri-Gum™
Flavors: Mint, Blood Orange, Pomegranate) & (CBG Infused
Tauri-Gum™ Flavor: Peach-Lemon). The Company’s
commercialization strategy consists of a broad array of retail
customers, distributors, and a fast-growing E-Commerce business
segment (E-Commerce website: www.taurigum.com). Please visit
our corporate website, for additional information, as well as
inquiries, at www.tauriga.com
Complementary to the
Company’s retail business, are its two ongoing biotechnology
initiatives. The first one relates to the development of a
Pharmaceutical grade version of Tauri-Gum™, for nausea regulation
(specifically designed to help patients that are subjected to
ongoing chemotherapy treatment). On March 18, 2020, the
Company announced that it filed a provisional U.S. patent
application covering its pharmaceutical grade version of
Tauri-Gum™. The Patent, filed with the U.S.P.T.O. is Titled
“MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS
OF TREATMENT”. The second one relates to a collaboration
agreement with Aegea Biotechnologies Inc. for the co-development of
a rapid, multiplexed, Novel Coronavirus (COVID-19) test with
superior sensitivity and
selectivity.
The Company is
headquartered in New York City and operates a regional office in
Barcelona, Spain. In addition, the Company operates a full
time E-Commerce fulfillment center located in LaGrangeville, New
York.
DISCLAIMER --
Forward-Looking Statements
This press release
contains certain “forward-looking statements” as defined by the
Private Securities Litigation Reform Act of 1995 which represent
management’s beliefs and assumptions concerning future events.
These forward-looking statements are often indicated by using words
such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,”
“believes,” or plans, and may include statements regarding
corporate objectives as well as the attainment of certain corporate
goals and milestones. Forward-looking statements are based on
present circumstances and on management’s present beliefs with
respect to events that have not occurred, that may not occur, or
that may occur with different consequences or timing than those now
assumed or anticipated. Actual results may differ materially from
those expressed in forward looking statements due to
known and unknown risks and uncertainties, such as are not
guarantees of general economic and business conditions, the ability
to successfully develop and market products, consumer and business
consumption habits, the ability to consummate successful
acquisition and licensing transactions, fluctuations in exchange
rates, and other factors over which Tauriga has little or no
control. Many of these risks and uncertainties are discussed in
greater detail in the “Risk Factors” section of Tauriga’s Form 10-K
and other filings made from time to time with the Securities and
Exchange Commission. Such forward-looking statements are made only
as of the date of this release, and Tauriga assumes no obligation
to update forward-looking statements to reflect subsequent events
or circumstances. You should not place undue reliance on these
forward-looking statements.
Contact:
CONTACT
INFORMATION
Tauriga Sciences, Inc.
555 Madison Avenue, 5th Floor
New York, NY 10022
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Instagram:
@taurigum
Twitter:
@SethMShaw
Corp. Website: www.tauriga.com
E-Commerce
Website: www.taurigum.com
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Apr 2023 to Apr 2024